D.C. Circuit Upholds FDA Rule On 180-Day Exclusivity
In a move that could have far-reaching implications for generic drug makers, the U.S. Court of Appeals for the D.C. Circuit has upheld a controversial U.S. Food and Drug Administration rule...To view the full article, register now.
Already a subscriber? Click here to view full article